Pharmaceutical companies are scrambling to develop obesity treatments that can compete with Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound. These two companies control roughly 90% of the $10 billion market for GLP-1 receptor agonists, the drug class that has transformed weight loss treatment since 2021.
Novo Nordisk and Eli Lilly built their lead on proven clinical results and manufacturing scale. Ozempic and Wegovy use semaglutide to regulate appetite and blood sugar. Mounjaro and Zepbound use tirzepatide, a dual-action compound that works on two separate hormone receptors. Both drugs require weekly injections and can cost $900 to $1,300 per month before insurance.
The race to compete involves multiple strategies. Some drugmakers pursue oral formulations. Others target specific patient populations, like those with heart disease or kidney problems. Still others hunt for drugs with fewer side effects than existing options. Amgen, Viking Therapeutics, Structure Therapeutics, and Roche are among the companies investing heavily in obesity programs.
The barrier to entry remains steep. Manufacturing these compounds at scale takes years and billions in capital. Clinical trials must prove efficacy and safety across tens of thousands of patients. Novo and Eli Lilly enjoy entrenched relationships with doctors, insurers, and pharmacy benefit managers.
Demand for obesity drugs continues to soar. An estimated 60 million Americans have obesity, and insurance coverage is expanding. The market could exceed $50 billion annually by 2030 if patient access widens. However, supply constraints and manufacturing bottlenecks persist, creating shortages that limit how quickly competitors can gain share.
For patients, competition could lower prices and expand options. Oral drugs in